Search PubMed⌕ Search

Biomedical subjects

F Giuliani

Publications and source records attributed to F Giuliani.

70 records · Page 4Linked to original sources
PubMedDate not supplied

Tumors and dental and ocular abnormalities after treatment of infant rats with adriamycin.

In rats repeatedly treated subcutaneously as infants with adriamycin in 2 cycles of 4 treatments each, the induction of ocular and dental abnormalities and tumors was studied. Cataracts appeared from 18 to 26 days in 80% of CD rats treated with 1.15 mg/kg/day of adriamycin and from 28 to 104 days in 55% of Wistar-Lewis rats given 0.75 mg/kg/day adriamycin. Abnormal growth of incisors was observed in 30% of the CD rats and in 44% of the Wistar-Lewis rats. At lower doses, no such abnormalities were found. At about 1 year after treatment, 100% of the CD rats treated with 0.75 mg/kg/day adriamycin and about 60% of the Wistar-Lewis rats treated with 0.75 and 0.5 mg/kg/day adriamycin developed tumors, which were histologically classified.

Adenoma↗
PubMedDate not supplied

Xeroradiographic evaluation of murine osteosarcoma.

Xeroradiography, a method of X-ray imaging based upon selenium photoconductivity, was used for the study of experimental osteosarcoma induced by MSV-M virus in rats. Due to the peculiar features of xeroradiographic image (enhancement of details and lowering of the overall contrast) good pictures of osseous structures together with soft tissues were obtained even in very young animals. Serially perfomred xeroradiographies gave a permanent representation of tumor evolution with time. Advantages and drawbacks of this method are discussed, particularly with respect to radiation dosage. Xeroradiography is proposed for the study of the response to antiblastic chemotherapy of experimental bone tumors.

Animals↗
PubMedDate not supplied

Carboplatin and etoposide in previously treated colorectal cancer patients.

AIMS AND BACKGROUND: Salvage treatment of advanced colorectal cancer patients has not been well defined as yet, and new potentially active drugs or combinations should be evaluated for these situations. METHODS: From February 1993 to September 1993, the combination of carboplatin (CBDCA) and etoposide (VP-16), both as 100 mg/m2 for three consecutive days, was administered to 17 colorectal cancer patients who had been previously subjected to FA-FU combination chemotherapy. The CBDCA + VP-16 treatment was repeated every 3 weeks. A total of 58 cycles was administered, and 16 patients were evaluable for response. RESULTS: There was no objective response, but 2 stable diseases and 14 progressive diseases were observed. Toxicity was mild, with no WHO 3-4 grade toxicity. CONCLUSION: This combination chemotherapy was judged ineffective for pretreated colorectal cancer patients.

Adult↗
PubMedDate not supplied

A phase II trial of etoposide, folinic acid, fluorouracil and epirubicin in advanced pancreatic carcinoma.

PURPOSE: Pancreatic carcinoma is generally considered a chemotherapy-resistant malignant neoplasm and to date there is no established chemotherapeutic treatment for patients with advanced disease. Many new combination regimens have been investigated to improve results. Modiano et al. (ASCO 1993; 12: 303) with ELF regimen (etoposide, folinic acid, and 5-fluorouracil) plus interferon obtained 6/7 partial remission in patients with advanced pancreatic cancer. Considering these interesting results and the therapeutic activity of epirubicin in this disease, we started a study (GOIM 9405) to verify the efficacy and safety of the ELFE (ELF + Epirubicin) regimen. PATIENTS AND METHODS: Twenty-three patients with advanced pancreatic cancer received etoposide 80 mg/m2 day 1-3, folinic acid (levo-isomer form) 100 mg/m2 day 1-3, 5-fluorouracil 340 mg/m2 day 1-3, and epirubicin 60 mg/m2 day 1. Treatment was repeated every three weeks. RESULTS: We obtained 3 PR, 4 SD and 13 PD. Overall response rate was 15% (95% CI: 3% to 38%) (intent to treat analysis: 13%; 95% CI: 3% to 34%). The median durations of response and survival were 9 and 5 months, respectively. Grade 3-4 WHO toxicity included diarrhoea (17%), mucositis (22%), leukopenia (17%). CONCLUSIONS: The ELFE regimen demonstrates scarce activity in patients with advanced pancreatic cancer, with mild toxicity.

Aged↗
PubMedDate not supplied

Infrared radiation exposure in traditional glass factories.

This article reports on a general method of evaluating exposure to infrared radiation (IR-A, IR-B, IR-C) from high temperature (T > 1000 degrees C) black body sources, simply by performing measurements with a luxometric and/or near IR detector. The method, which may be applied to any black body source, uses the universality of the Planck formula for the black body spectrum, which allows estimation of the radiated power in any wavelength range by measuring the power radiated in another range. This capability may be very useful when the range of interest is one in which radiometers are expensive and difficult to calibrate, as for the IR-B and IR-C ranges, because a more commonly available luxometer can be used instead. The results of measurements and evaluations in two traditional Italian glass factories are reported and compared with the threshold limit value given by the American Conference of Governmental Industrial Hygienists. Intense exposures in the IR-B and IR-C ranges has been found for some workers, exceeding the limit by a large factor. This exposure must be reduced, as it has been shown by epidemiologic studies that there is indeed a correlation between cataractogenesis and work with fused glass and metals.

Cataract↗
PubMedDate not supplied

[Clinical guidelines for the management of gastrointestinal stromal tumors].

Treatment of gastrointestinal stromal tumors (GIST) has been revolutioned by the recently discovered molecular mechanism responsible for the oncogenesis of this disease. In addition, due to the rapid progress at molecular and clinical level observed in the last few years, there is a need to review the current state of the art in order to delineate appropriate guidelines for the optimal management of these tumors. A panel of experts from several specialities, including medical oncology, surgery, pathology, molecular biology and imaging, were invited to participate in a meeting to present and discuss a number of pre-selected questions, and to achieve a consensus according to the categories of the National Comprehensive Cancer Network (NCCN) and the Standard Options Recommandations (SOR) of the French Federation of Cancer Centers. Generally, consensus points were from categories 2A of the NCCN and B2 of the SOR. Conventional histologic examination with immunohistochemistry for CD117, CD34, SMA, S-100 and desmin is considered standard. Molecular analysis for the identification of KIT and PDGFRA mutation may be indicated in CD117-negative GIST. Complete tumor resection with negative margins is the optimal surgical treatment. Adjuvant imatinib should be considered an experimental approach. Neoadjuvant imatinib is also experimental, although its use may be justified in unresectable or marginally resectable GIST. Imatinib should be started in metastatic or recurrent disease, and should be continued until progressive disease or drug intolerance. In these cases, sunitinib can be used. The optimal criteria for the assessment and monitoring of GIST undergoing imatinib therapy are not well known, but they should include reduction in tumor size and disease stabilization, as well as reduction of tumor density on CT scan and metabolic activity on PET scan.

Antineoplastic Agents↗
PubMedDate not supplied

[Changes in hormonal and biochemical parameters in gastric adenocarcinoma].

In 51 patients with gastric adenocarcinoma the fasting blood concentrations of hCG, beta hCG, alpha subunits, ADH, calcitonin, enteroglucagon, gastrin, GH, melatonin, somatostatin, estradiol, CEA and pepsinogen I in the peripheral vein were estimated by radioimmunoassay at the time of diagnosis and, in those who underwent surgery, 7 days after the operation, to determine the incidence of the modifications of the above mentioned substances' blood levels and the existence of possible markers. In presence of increases of the examined parameters greater than 50%, considering M +/- 2 SD of 10 control subjects as normal range, the tumours were examined immunohistochemically. In patients with gastric adenocarcinoma, in comparison with normal subjects, we found significant higher blood levels of hCG alpha subunits, gastrin and CEA and lower of melatonin, pepsinogen I and GH. The immunohistological results demonstrated CEA in both examined cases, alpha subunits in 2 of 6 (respectively in dysplasic areas and in surrounding non neoplastic mucosa) and enteroglucagon in 1 of 3 (dysplasic areas). Our results indicate that none of the parameters we examined, because of their non-specificity or of the low incidence of their modifications, can be considered a marker of gastric adenocarcinoma.

Adenocarcinoma↗
PubMedDate not supplied

Effect of naloxone on TRH-induced PRL and TSH response in normal man.

The effect of naloxone on PRL and TSH response to TRH was studied in 8 normal men. PRL response to TRH was unaffected by the administration of naloxone. TSH response to TRH was significantly decreased by naloxone, considering the maximum absolute increment (p less than 0.01) and the areas under curves (p less than 0.05). In conclusion, the PRL response to TRH may be unaffected by endogenous opioids or naloxone and we were unable to reveal a possible opioid effect in our experimental conditions. TSH response to TRH seems to be affected by endogenous opioids, possibly due to an indirect or direct action on TRH and/or on the pituitary.

Adult↗
PubMedDate not supplied

[Determination of prolactin secretion in idiopathic galactorrhea].

We have studied 15 women with idiopathic galactorrhoea and normal serum PRL basal values, regularly menstruating, with normal x-ray of the sella turcica and mammography. The patients were not suffering from other endocrine diseases nor taking medications known to cause galactorrhoea. These subjects and 5 normal women were submitted to an evaluation of the serum PRL circadian rhythm, to TRH test for PRL and TSH, metoclopramide test for PRL, and basal determination of TT3 and TT4. The results did not show any significant difference between the two groups and did not reveal any abnormality of PRL secretion in the patients. These data, resulting from a homogeneous series of patients, support the hypothesis of an increased sensitivity of breast receptors to PRL, or of the secretion of heterogeneous forms of PRL, biologically active on mammary tissue, but not detected by current RIA methods for PRL.

Adult↗
PubMedDate not supplied

Differences in cortisol, aldosterone and testosterone responses to ACTH 1-17 administered at two different times of day.

The effects of 100 micrograms, i.m. of the analog ACTH 1-17 administered at 0800 and 1800 on the secretion of cortisol, aldosterone and testosterone have been studied in normal subjects: 8 male and 8 female. The group as a whole and the males had significantly greater absolute and percent increments in plasma cortisol after administration at 1800. In the females, there was only a greater percent increment in cortisol after the evening administration. The heptadecapeptide always significantly stimulated serum aldosterone, with no difference between the two times of administration. In the females, ACTH 1-17 significantly stimulated testosterone, with a more protracted secretion after the evening administration. In the males, there was always a significant testosterone decrease after the administration of the drug, with no difference between morning and evening. In conclusion, 100 micrograms i.m. of the analog ACTH 1-17 stimulates cortisol secretion more when given during the circadian nadir of plasma cortisol, but only in men. ACTH 1-17 increases testosterone in women and decreases it in men, whereas it seems to increase aldosterone secretion in both sexes.

Adolescent↗
PubMedDate not supplied

[Anti-toxoplasma antibody titers and immunoglobulins].

285 sera from parturient patients have been tested for the presence of anti-toxoplasma antibodies by the direct Agglutination test and for Immunoglobulins by the immunochemical turbidimetric determination. 17 sera showed a significant increase in the titre of anti-toxoplasma antibodies; 5 of these 17 presented a simultaneous IgM level increase, subsequently confirmed by a 2 Mercaptoethanol pretreatment, this fact suggesting the presence of active infectious disease. The authors think it can be useful in the diagnostic assessment of active toxoplasmic infectious disease the simultaneous screening of sera by the two described methods: the direct Agglutination test and the immunochemical turbidimetric determination.

Agglutination Tests↗
PubMedDate not supplied

Studies in mice treated with ICRF-159 combined with daunorubicin or doxorubicin.

We have investigated the effect of ICRF-159 on the toxicity of daunorubicin (DR) and doxorubicin (DX) given iv, and the effectiveness of ICRF-159 combined with DR or DX on the growth of transplantable MLV-M (murine leukemia virus-Moloney) leukemia, MS-2 solid sarcoma, and pulmonary MS-2 metastases in mice. The injection of ICRF-159 concurrently with the administration of DR resulted in a marked decrease in the toxicity of the antibiotic. However, when DX was injected concurrently with ICRF-159 an increase in antibiotic toxicity was observed, except when ICRF-159 was employed at a very low dosage. ICRF-159 administered alone did not influence the tumor growth in the systems tested and did not result in antimetastatic activity. In mice bearing transplanted MLV-M leukemia, the effects of the combination of ICRF-159 with DR or DX were not superior to those of DR or DX treatment on either tumor growth or lifespan. The treatment of MS-2 tumor with the ICRF-159 and DX combination neither produced a therapeutic synergism (therapeutic response superior to the maximum response obtainable by either agent independently) nor antagonized the antineoplastic action of DX. A marked inhibition of tumor growth and increase in lifespan were observed in the mice treated with a high dose of DR (10 mg/kg/injection) plus ICRF-159 (50 mg/kg/injection). We have also examined, on MS-2 lung metastases, the effectiveness of surgical-adjuvant combination chemotherapy with DR or DX plus ICRF-159 injected at different times with respect to surgery. A synergistic effect of DX or DR with ICRF-159 was observed when the drug treatment was performed before the surgery, or both before and after the surgery. No synergistic effect of DX or DR with ICRF-159 on MS-2 lung metastases was found when the MS-2 lung metastases were treated after the surgery. A higher antimetastatic activity was observed in the groups treated with a combination of toxic doses of DR and ICRF-150 than in the groups treated with a combination of toxic doses of DR and ICRF-159 than in the groups treated with tolerated doses of the antibiotic.

Animals↗
PubMedDate not supplied

Biochemical modulation of fluorouracil with high dose methotrexate or folinic acid in advanced colorectal cancer patients. Gruppo Oncologico dell' Italia Meridionale (GOIM).

To compare the efficacy of two biochemical modulations of 5-Fluorouracil in advanced colorectal cancer, 104 patients were randomized to receive high dose methotrexate followed by 5-Fluorouracil and leucovorin rescue on day 1 (Arm A) or folinic acid and 5-Fluorouracil on day 1 to 5 (Arm B). Both treatments were repeated every 3 weeks. In the 92 evaluable patients, objective responses were observed in 34% in Arm A and 31% in Arm B, with a median duration of 7.5 and 8.5 months, respectively. Median overall survival was similar in both groups (12 versus 13 months, respectively). A statistically significant difference was found only between responders and non responders of group B (p = 0.004). Toxicity was mild. In conclusion, no difference in therapeutic activity was seen between the two treatments and additional biochemical modulation must be evaluated.

Adult↗